JRContrerasR's profile picture. Congenital and Heart Transplant Fellow. Latin American Cardiac Surgeon. Dad 🇨🇱🇨🇦

Juan Contreras

@JRContrerasR

Congenital and Heart Transplant Fellow. Latin American Cardiac Surgeon. Dad 🇨🇱🇨🇦

Juan Contreras さんがリポスト

SAVR after TAVR at #eacts2025 by Gregory Fontana Doesn’t look Good… the industry and the Interventional cardiologist will keep pushing further… but the data is right there. (Btw: totally agree with: is TAVI not TAVR!)

loremontesvilla's tweet image. SAVR after TAVR at #eacts2025 by Gregory Fontana

Doesn’t look Good… the industry and the Interventional cardiologist will keep pushing further… but the data is right there. 

(Btw: totally agree with: is TAVI not TAVR!)
loremontesvilla's tweet image. SAVR after TAVR at #eacts2025 by Gregory Fontana

Doesn’t look Good… the industry and the Interventional cardiologist will keep pushing further… but the data is right there. 

(Btw: totally agree with: is TAVI not TAVR!)

Juan Contreras さんがリポスト

So… no more DAPT post CABG!!! (After Acute Coronary Sindrome). Aspirin vs DAPT: More major bleeding events, same MACE. #eacts2025 #CABG

loremontesvilla's tweet image. So… no more DAPT post CABG!!! (After Acute Coronary Sindrome). Aspirin vs DAPT: More major bleeding events, same MACE. #eacts2025 #CABG

Nuevo curso de LACES Academy. Manejo perioperatorio. Comienza el 1 de Octubre !

VictorDayan1's tweet image. Nuevo curso de LACES Academy. Manejo perioperatorio. Comienza el 1 de Octubre !


Juan Contreras さんがリポスト

Nuevo curso de LACES Academy. Manejo perioperatorio. Comienza el 1 de Octubre !

VictorDayan1's tweet image. Nuevo curso de LACES Academy. Manejo perioperatorio. Comienza el 1 de Octubre !

Juan Contreras さんがリポスト

We want to hear your feedback on the beta version of the AQG Adult Cardiac Risk Calculator. @EdSolteszMD explains below that this tool is able to predict mortality for virtually all cardiac procedures. Explore the features and share your feedback: riskcalculator.aatsqualitygateway.org


Muy Buen Analisis de @VictorDayan1 . 100 % recomendado leerlo completo

🚨2025 @EACTS and @ESC_Journals guidelines have been released. Great job by those involved. As all non evidences based recommendations, most are subject to different perspectives. The authors of current guidelines have jeopardized the future of pts who need a second procedure…

VictorDayan1's tweet image. 🚨2025 @EACTS and @ESC_Journals guidelines have been released. Great job by those involved. As all non evidences based recommendations, most are subject to different perspectives. The authors of current guidelines have jeopardized the future of pts who need a second procedure…


Juan Contreras さんがリポスト

Objective and scientific. That is why we need more of @VictorDayan1 on guidelines

🚨2025 @EACTS and @ESC_Journals guidelines have been released. Great job by those involved. As all non evidences based recommendations, most are subject to different perspectives. The authors of current guidelines have jeopardized the future of pts who need a second procedure…

VictorDayan1's tweet image. 🚨2025 @EACTS and @ESC_Journals guidelines have been released. Great job by those involved. As all non evidences based recommendations, most are subject to different perspectives. The authors of current guidelines have jeopardized the future of pts who need a second procedure…


Juan Contreras さんがリポスト

Prophylactic VA #ECMO during complex/high-risk percutaneous coronary intervention 🔍 70 pts w SYNTAX ≥33 (declined CABG): prophylactic #ECLS prior to elective PCI vs not ⚖️ life-threatening complications (CA unresponsive to CPR, CS, acute unresponsive LV failure, refractory…

FOAMecmo's tweet image. Prophylactic VA #ECMO during complex/high-risk percutaneous coronary intervention
🔍 70 pts w SYNTAX ≥33 (declined CABG): prophylactic #ECLS prior to elective PCI vs not 
⚖️ life-threatening complications (CA unresponsive to CPR, CS, acute unresponsive LV failure, refractory…

Juan Contreras さんがリポスト

10y PARTNER II outcomes🫣😱 accessdata.fda.gov/scripts/cdrh/c…

manuel_carnero's tweet image. 10y PARTNER II outcomes🫣😱

accessdata.fda.gov/scripts/cdrh/c…

Juan Contreras さんがリポスト

📖👓 Utilidad Angio-TC cardíaco en la evaluación de la endocarditis infecciosa. Una revision de hallazgos en casos locales, lee el artículo completo acá ➡️ revistamedicadechile.cl/index.php/rmed… @marzagod @medufro @AlemanaTemuco @HHHATEMUCO

RADdschneider's tweet image. 📖👓 Utilidad Angio-TC cardíaco en la evaluación de la endocarditis infecciosa. Una revision de hallazgos en casos locales, lee el artículo completo acá ➡️ revistamedicadechile.cl/index.php/rmed… @marzagod @medufro @AlemanaTemuco @HHHATEMUCO
RADdschneider's tweet image. 📖👓 Utilidad Angio-TC cardíaco en la evaluación de la endocarditis infecciosa. Una revision de hallazgos en casos locales, lee el artículo completo acá ➡️ revistamedicadechile.cl/index.php/rmed… @marzagod @medufro @AlemanaTemuco @HHHATEMUCO
RADdschneider's tweet image. 📖👓 Utilidad Angio-TC cardíaco en la evaluación de la endocarditis infecciosa. Una revision de hallazgos en casos locales, lee el artículo completo acá ➡️ revistamedicadechile.cl/index.php/rmed… @marzagod @medufro @AlemanaTemuco @HHHATEMUCO

Gracias por la oportunidad de permitirnos mostrar nuestro trabajo en pacientes con cardiopatías congénitas instagram.com/p/DMnl5whAnU64…


Outstanding symposium, congratulation @OuzounianMD for lead the most important meeting of 2025 @UHN

JRContrerasR's tweet image. Outstanding symposium, congratulation @OuzounianMD for lead the most important meeting of 2025 @UHN
JRContrerasR's tweet image. Outstanding symposium, congratulation @OuzounianMD for lead the most important meeting of 2025 @UHN
JRContrerasR's tweet image. Outstanding symposium, congratulation @OuzounianMD for lead the most important meeting of 2025 @UHN
JRContrerasR's tweet image. Outstanding symposium, congratulation @OuzounianMD for lead the most important meeting of 2025 @UHN

Felicidades al autor muy buen análisis

Vía crucis de TAVI versus cirugía en bajo riesgo: las tres negaciones secce.es/via-crucis-de-…

SECTCV's tweet image. Vía crucis de TAVI versus cirugía en bajo riesgo: las tres negaciones

secce.es/via-crucis-de-…


Juan Contreras さんがリポスト

Vía crucis de TAVI versus cirugía en bajo riesgo: las tres negaciones secce.es/via-crucis-de-…

SECTCV's tweet image. Vía crucis de TAVI versus cirugía en bajo riesgo: las tres negaciones

secce.es/via-crucis-de-…

Women in CV medicine . A model for new generations @OuzounianMD

JRContrerasR's tweet image. Women in CV medicine . A model for new generations
@OuzounianMD

Following the second session: how to I teach it: sequential or isolated distal anastomosis by Dr. Sabik @LATAM_LACES @EACTS @STS_CTsurgery

JRContrerasR's tweet image. Following the second session: how to I teach it: sequential or isolated distal anastomosis  by Dr. Sabik
@LATAM_LACES @EACTS @STS_CTsurgery
JRContrerasR's tweet image. Following the second session: how to I teach it: sequential or isolated distal anastomosis  by Dr. Sabik
@LATAM_LACES @EACTS @STS_CTsurgery

Juan Contreras さんがリポスト

⭐ We can't wait to open our doors and welcome you to the 2024 EACTS/STS/LACES Latin America Cardiovascular Surgery Conference - starting tomorrow!⭐ 📍 Sheraton Buenos Aires Hotel & Convention Center, San Martín 1225 1275, C1104 CABA, Argentina 🕐 Registration desk opening…


Loading...

Something went wrong.


Something went wrong.